Cisplatin, Capecitabine, Telatinib — Competitive Intelligence Brief

Cisplatin, Capecitabine, Telatinib (Cisplatin, Capecitabine, Telatinib) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Platinum-based chemotherapy, Antimetabolite, Tyrosine kinase inhibitor. Area: Oncology.

phase 2 Platinum-based chemotherapy, Antimetabolite, Tyrosine kinase inhibitor DNA, Thymidylate synthase, VEGFR, PDGFR Oncology Small molecule

Target snapshot

Cisplatin, Capecitabine, Telatinib (Cisplatin, Capecitabine, Telatinib) — ACT Biotech, Inc. Cisplatin works by crosslinking DNA, thereby inhibiting DNA replication and transcription, while Capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase, and Telatinib is a tyrosine kinase inhibitor that targets the VEGFR and PDGFR pathways.

Comparator set

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cisplatin, Capecitabine, Telatinib TARGET	Cisplatin, Capecitabine, Telatinib	ACT Biotech, Inc	phase 2	Platinum-based chemotherapy, Antimetabolite, Tyrosine kinase inhibitor	DNA, Thymidylate synthase, VEGFR, PDGFR

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Platinum-based chemotherapy, Antimetabolite, Tyrosine kinase inhibitor class)

1. ACT Biotech, Inc · 1 drug in this class